Effects of L-DOPA and STN-HFS dyskinesiogenic treatments on NR2B regulation in basal ganglia in the rat model of Parkinson's disease

Neurobiology of Disease

Volumn 48, Issue 3, 2012, Pages 379-390

  Quintana, Adrien ^a,b   Sgambato Faure, Véronique ^a,d   Savasta, Marc ^a,b,c  

^a INSERM   (France)

^b UNIV GRENOBLE ALPES   (France)

^c GRENOBLE UNIVERSITY HOSPITAL   (France)

^d UNIVERSITÉ LYON 1   (France)

Author keywords

6 OHDA lesion; Basal ganglia; Dyskinesia; Glutamate; High frequency stimulation; L DOPA; NMDA receptors; NR2B; Parkinson's disease

Indexed keywords

BENSERAZIDE; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; TRAXOPRODIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN DEPTH STIMULATION; BRAIN TISSUE; CONTROLLED STUDY; CORPUS STRIATUM; DENERVATION; DRUG MEGADOSE; DYSKINESIA; ELECTRODE; HISTOLOGY; IMMUNOHISTOCHEMISTRY; LOCOMOTION; MALE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REGULATORY MECHANISM; RODENT; SUBTHALAMIC NUCLEUS;

ANIMALS; BASAL GANGLIA; DEEP BRAIN STIMULATION; DOPAMINE AGENTS; DYSKINESIAS; ELECTRODES, IMPLANTED; IMMUNOHISTOCHEMISTRY; LEVODOPA; MALE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; SUBTHALAMIC NUCLEUS;

EID: 84864917734     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2012.06.009     Document Type: Article

References (87)

1. Ahlskog J.E., Muenter M.D. Frequency of L-DOPA-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov. Disord. 2001, 16(3):448-458.
2. Anderson M.E., Postupna N., Ruffo M. Effects of high-frequency stimulation in the internal globus pallidus on the activity of thalamic neurons in the awake monkey. J. Neurophysiol. 2003, 89:1150-1160.
3. Andersson M., Hilbertson A., Cenci M.A. Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson's disease. Neurobiol. Dis. 1999, 6:461-474.
4. Aubert I., Guigoni C., Li Q., Dovero S., Bioulac B.H., Gross C.E., Crossman A.R., Bloch B., Bezard E. Enhanced preproenkephalin-B-derived opioid transmission in striatum and subthalamic nucleus converges upon globus pallidus internalis in L-3,4-dihydroxyphenylalanine-induced dyskinesia. Biol. Psychiatry 2007, 61:836-844.
5. Aziz T.Z., Peggs D., Sambrook M.A., Crossman A.R. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Mov. Disord. 1991, 6:288-292.
6. Bacci J.J., Absi el H., Manrique C., Baunez C., Salin P., Kerkerian-Le Goff L. Differential effects of prolonged high frequency stimulation and of excitotoxic lesion of the subthalamic nucleus on dopamine denervation-induced cellular defects in the rat striatum and globus pallidus. Eur. J. Neurosci. 2004, 20:3331-3341.
7. Barbeau A. L-dopa therapy in Parkinson's disease: a critical review of nine years' experience. Can. Med. Assoc. J. 1969, 101:59-68.
8. Bejjani B., Damier P., Arnulf I., Bonnet A.M., Vidailhet M., Dormont D., Pidoux B., Cornu P., Marsault C., Agid Y. Pallidal stimulation for Parkinson's disease. Two targets?. Neurology 1997, 49:1564-1569.
9. Benabid A.L., Benazzouz A., Limousin P., Koudsie A., Krack P., Piallat B., Pollak P. Dyskinesias and the subthalamic nucleus. Ann. Neurol. 2000, 47:S189-S192.
10. Benazzouz A., Gross C., Feger J., Boraud T., Bioulac B. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur. J. Neurosci. 1993, 5:382-389.
11. Benazzouz A., Piallat B., Pollak P., Benabid A.L. Responses of substantia nigra pars reticulata and globus pallidus complex to high frequency stimulation of the subthalamic nucleus in rats: electrophysiological data. Neurosci. Lett. 1995, 189:77-80.
12. Benazzouz A., Gao D.M., Ni Z.G., Piallat B., Bouali-Benazzouz R., Benabid A.L. Effect of high-frequency stimulation of the subthalamic nucleus on the neuronal activities of the substantia nigra pars reticulata and ventrolateral nucleus of the thalamus in the rat. Neuroscience 2000, 99:289-295.
13. Benazzouz A., Tai C.H., Meissner W., Bioulac B., Bezard E., Gross C. High-frequency stimulation of both zona incerta and subthalamic nucleus induces a similar normalization of basal ganglia metabolic activity in experimental parkinsonism. FASEB J. 2004, 18:528-530.
14. Bergman H., Wichmann T., DeLong M.R. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990, 249:1436-1438.
15. Beurrier C., Bezard E., Bioulac B., Gross C. Subthalamic stimulation elicits hemiballismus in normal monkey. Neuroreport 1997, 8:1625-1629.
16. Birkmayer W., Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wien. Klin. Wochenschr. 1961, 73:787-788.
17. Blanchet P.J., Calon F., Morissette M., Hadj Tahar A., Belanger N., Samadi P., Grondin R., Gregoire L., Meltzer L., Di Paolo T., Bedard P.J. Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms. Parkinsonism Relat. Disord. 2004, 10:297-304.
18. Blandini F., Greenamyre J.T., Fancellu R., Nappi G. Blockade of subthalamic glutamatergic activity corrects changes in neuronal metabolism and motor behavior in rats with nigrostriatal lesions. Neurol. Sci. 2001, 22:49-50.
19. Boraud T., Bezard E., Guehl D., Bioulac B., Gross C. Effects of L-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey. Brain Res. 1998, 787:157-160.
20. Boraud T., Bezard E., Bioulac B., Gross C.E. Dopamine agonist-induced dyskinesias are correlated to both firing pattern and frequency alterations of pallidal neurones in the MPTP-treated monkey. Brain 2001, 124:546-557.
21. Boulet S., Lacombe E., Carcenac C., Feuerstein C., Sgambato-Faure V., Poupard A., Savasta M. Subthalamic stimulation-induced forelimb dyskinesias are linked to an increase in glutamate levels in the substantia nigra pars reticulata. J. Neurosci. 2006, 26:10768-10776.
22. Bruet N., Windels F., Carcenac C., Feuerstein C., Bertrand A., Poupard A., Savasta M. Neurochemical mechanisms induced by high frequency stimulation of the subthalamic nucleus: increase of extracellular striatal glutamate and GABA in normal and hemiparkinsonian rats. J. Neuropathol. Exp. Neurol. 2003, 62:1228-1240.
23. Calabresi P., Mercuri N.B., Sancesario G., Bernardi G. Electrophysiology of dopamine-denervated striatal neurons. Implications for Parkinson's disease. Brain 1993, 116(Pt 2):433-452.
24. Calon F., Morissette M., Ghribi O., Goulet M., Grondin R., Blanchet P.J., Bedard P.J., Di Paolo T. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry 2002, 26:127-138.
25. Calon F., Rajput A.H., Hornykiewicz O., Bedard P.J., Di Paolo T. Levodopa-induced motor complications are associated with alterations of glutamate receptors in Parkinson's disease. Neurobiol. Dis. 2003, 14:404-416.
26. Carpenter M.B., Whittier J.R., Mettler F.A. Analysis of choreoid hyperkinesia in the Rhesus monkey; surgical and pharmacological analysis of hyperkinesia resulting from lesions in the subthalamic nucleus of Luys. J. Comp. Neurol. 1950, 92:293-331.
27. Cenci M.A., Lindgren H.S. Advances in understanding L-DOPA-induced dyskinesia. Curr. Opin. Neurobiol. 2007, 17:665-671.
28. Cenci M.A., Lee C.S., Bjorklund A. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA. Eur. J. Neurosci. 1998, 10:2694-2706.
29. Chase T.N., Oh J.D. Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism. Trends Neurosci. 2000, 23:S86-S91.
30. Dekundy A., Lundblad M., Danysz W., Cenci M.A. Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: further validation of the rat dyskinesia model. Behav. Brain Res. 2007, 179(1):76-89.
31. Del Dotto P., Pavese N., Gambaccini G., Bernardini S., Metman L.V., Chase T.N., Bonuccelli U. Intravenous amantadine improves levadopa-induced dyskinesias: an acute double-blind placebo-controlled study. Mov. Disord. 2001, 16(3):515-520.
32. Dunah A.W., Wang Y., Yasuda R.P., Kameyama K., Huganir R.L., Wolfe B.B., Standaert D.G. Alterations in subunit expression, composition, and phosphorylation of striatal N-methyl-D-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease. Mol. Pharmacol. 2000, 57:342-352.
33. El Atifi-Borel M., Buggia-Prevot V., Platet N., Benabid A.L., Berger F., Sgambato-Faure V. De novo and long-term l-Dopa induce both common and distinct striatal gene profiles in the hemiparkinsonian rat. Neurobiol. Dis. 2009, 34:340-350.
34. Gradinaru V., Mogri M., Thompson K.R., Henderson J.M., Deisseroth K. Optical deconstruction of parkinsonian neural circuitry. Science 2009, 324:354-359.
35. Greenamyre J.T. Glutamatergic influences on the basal ganglia. Clin. Neuropharmacol. 2001, 24:65-70.
36. Gubellini P., Picconi B., Bari M., Battista N., Calabresi P., Centonze D., Bernardi G., Finazzi-Agro A., Maccarrone M. Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci. 2002, 22:6900-6907.
37. Guridi J., Obeso J.A. The subthalamic nucleus, hemiballismus and Parkinson's disease: reappraisal of a neurosurgical dogma. Brain 2001, 124:5-19.
38. Guridi J., Herrero M.T., Luquin M.R., Guillen J., Ruberg M., Laguna J., Vila M., Javoy-Agid F., Agid Y., Hirsch E., Obeso J.A. Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis. Brain 1996, 119(Pt 5):1717-1727.
39. Hadj Tahar A., Gregoire L., Darre A., Belanger N., Meltzer L., Bedard P.J. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiol. Dis. 2004, 15:171-176.
40. Hallett P.J., Dunah A.W., Ravenscroft P., Zhou S., Bezard E., Crossman A.R., Brotchie J.M., Standaert D.G. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 2005, 48:503-516.
41. Hamada I., DeLong M.R. Excitotoxic acid lesions of the primate subthalamic nucleus result in transient dyskinesias of the contralateral limbs. J. Neurophysiol. 1992, 68:1850-1858.
42. Hammond C., Feger J., Bioulac B., Souteyrand J.P. Experimental hemiballism in the monkey produced by unilateral kainic acid lesion in corpus Luysii. Brain Res. 1979, 171:577-580.
43. Hashimoto T., Elder C.M., Okun M.S., Patrick S.K., Vitek J.L. Stimulation of the subthalamic nucleus changes the firing pattern of pallidal neurons. J. Neurosci. 2003, 23:1916-1923.
44. Hirsch E.C., Perier C., Orieux G., Francois C., Feger J., Yelnik J., Vila M., Levy R., Tolosa E.S., Marin C., Trinidad Herrero M., Obeso J.A., Agid Y. Metabolic effects of nigrostriatal denervation in basal ganglia. Trends Neurosci. 2000, 23:S78-S85.
45. Hurley M.J., Jackson M.J., Smith L.A., Rose S., Jenner P. Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets. Eur. J. Neurosci. 2005, 21:3240-3250.
46. Jonkers N., Sarre S., Ebinger G., Michotte Y. MK801 suppresses the L-DOPA-induced increase of glutamate in striatum of hemi-Parkinson rats. Brain Res. 2002, 926:149-155.
47. Krack P., Pollak P., Limousin P., Benazzouz A., Deuschl G., Benabid A.L. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity. Brain 1999, 122(Pt 6):1133-1146.
48. Krack P., Batir A., Van Blercom N., Chabardes S., Fraix V., Ardouin C., Koudsie A., Limousin P.D., Benazzouz A., LeBas J.F., Benabid A.L., Pollak P. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N. Engl. J. Med. 2003, 349:1925-1934.
49. Lacombe E., Khaindrava V., Melon C., Oueslati A., Kerkerian-Le Goff L., Salin P. Different functional basal ganglia subcircuits associated with anti-akinetic and dyskinesiogenic effects of antiparkinsonian therapies. Neurobiol. Dis. 2009, 36:116-125.
50. Limousin P., Pollak P., Benazzouz A., Hoffmann D., Le Bas J.F., Broussolle E., Perret J.E., Benabid A.L. Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995, 345:91-95.
51. Limousin P., Pollak P., Hoffmann D., Benazzouz A., Perret J.E., Benabid A.L. Abnormal involuntary movements induced by subthalamic nucleus stimulation in parkinsonian patients. Mov. Disord. 1996, 11:231-235.
52. Lindefors N., Ungerstedt U. Bilateral regulation of glutamate tissue and extracellular levels in caudate-putamen by midbrain dopamine neurons. Neurosci. Lett. 1990, 115:248-252.
53. Loftis J.M., Janowsky A. The N-methyl-D-aspartate receptor subunit NR2B: localization, functional properties, regulation, and clinical implications. Pharmacol. Ther. 2003, 97:55-85.
54. Maurice N., Thierry A.M., Glowinski J., Deniau J.M. Spontaneous and evoked activity of substantia nigra pars reticulata neurons during high-frequency stimulation of the subthalamic nucleus. J. Neurosci. 2003, 23:9929-9936.
55. Menegoz M., Lau L.F., Herve D., Huganir R.L., Girault J.A. Tyrosine phosphorylation of NMDA receptor in rat striatum: effects of 6-OH-dopamine lesions. Neuroreport 1995, 7:125-128.
56. Morissette M., Dridi M., Calon F., Hadj Tahar A., Meltzer L.T., Bedard P.J., Di Paolo T. Prevention of levodopa-induced dyskinesias by a selective NR1A/2B N-methyl-D-aspartate receptor antagonist in parkinsonian monkeys: implication of preproenkephalin. Mov. Disord. 2006, 21:9-17.
57. Moro E., Esselink R.J., Benabid A.L., Pollak P. Response to levodopa in parkinsonian patients with bilateral subthalamic nucleus stimulation. Brain 2002, 125:2408-2417.
58. Nash J.E., Ravenscroft P., McGuire S., Crossman A.R., Menniti F.S., Brotchie J.M. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Exp. Neurol. 2004, 188:471-479.
59. Nutt J.G., Gunzler S.A., Kirchhoff T., Hogarth P., Weaver J.L., Krams M., Jamerson B., Menniti F.S., Landen J.W. Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism. Mov. Disord. 2008, 23(13):1860-1866.
60. O'Dell S.J., Marshall J.F. Chronic L-dopa alters striatal NMDA receptors in rats with dopaminergic injury. Neuroreport 1996, 7:2457-2461.
61. Oh J.D., Russell D.S., Vaughan C.L., Chase T.N. Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and L-DOPA administration. Brain Res. 1998, 813:150-159.
62. Papa S.M., Boldry R.C., Engber T.M., Kask A.M., Chase T.N. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res. 1995, 701:13-18.
63. Paxinos G., Watson C. The rat brain. In stereotaxic coordinates 1982, Academic Press, San Diego. fourth edition.
64. Peretti-Renucci R., Feuerstein C., Manier M., Lorimier P., Savasta M., Thibault J., Mons N., Geffard M. Quantitative image analysis with densitometry for immunohistochemistry and autoradiography of receptor binding sites-methodological considerations. J. Neurosci. Res. 1991, 28:583-600.
65. Pollak P., Benabid A.L., Gross C., Gao D.M., Laurent A., Benazzouz A., Hoffmann D., Gentil M., Perret J. Effects of the stimulation of the subthalamic nucleus in Parkinson disease. Rev. Neurol. (Paris) 1993, 149:175-176.
66. Porter R.H., Greene J.G., Higgins D.S., Greenamyre J.T. Polysynaptic regulation of glutamate receptors and mitochondrial enzyme activities in the basal ganglia of rats with unilateral dopamine depletion. J. Neurosci. 1994, 14:7192-7199.
67. Putterman D.B., Munhall A.C., Kozell L.B., Belknap J.K., Johnson S.W. Evaluation of levodopa dose and magnitude of dopamine depletion as risk factors for levodopa-induced dyskinesia in a rat model of Parkinson's disease. J. Pharmacol. Exp. Ther. 2007, 323:277-284.
68. Quintana A., Melon C., Kerkerian-Le Goff L., Salin P., Savasta M., Sgambato-Faure V. Forelimb dyskinesia mediated by high-frequency stimulation of the subthalamic nucleus is linked to rapid activation of the NR2B subunit of N-methyl-D-aspartate receptors. Eur. J. Neurosci. 2010, 32:423-434.
69. Rascol O., Fabre N. Dyskinesia: L-dopa-induced and tardive dyskinesia. Clin. Neuropharmacol. 2001, 24:313-323.
70. Rylander D., Recchia A., Mela F., Dekundy A., Danysz W., Cenci M.A. Pharmacological modulation of glutamate transmission in a rat model of L-DOPA-induced dyskinesia: effects on motor behavior and striatal nuclear signaling. J. Pharmacol. Exp. Ther. 2009, 330:227-235.
71. Salin P., Manrique C., Forni C., Kerkerian-Le Goff L. High-frequency stimulation of the subthalamic nucleus selectively reverses dopamine denervation-induced cellular defects in the output structures of the basal ganglia in the rat. J. Neurosci. 2002, 22:5137-5148.
72. Sgambato-Faure V., Cenci M.A. Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease. Prog. Neurobiol. 2012, 96(1):69-86. Epub 2011 Nov 3.
73. Sgambato V., Vanhoutte P., Pagès C., Rogard M., Hipskind R., Besson M.J., Caboche J. In vivo expression and regulation of Elk-1, a target of the extracellular-regulated kinase signaling pathway, in the adult rat brain. J. Neurosci. 1998, 18(1):214-226.
74. Sgambato-Faure V., Buggia V., Gilbert F., Levesque D., Benabid A.L., Berger F. Coordinated and spatial upregulation of arc in striatonigral neurons correlates with L-dopa-induced behavioral sensitization in dyskinetic rats. J. Neuropathol. Exp. Neurol. 2005, 64:936-947.
75. Soderstrom K.E., Meredith G., Freeman T.B., McGuire S.O., Collier T.J., Sortwell C.E., Wu Q., Steece-Collier K. The synaptic impact of the host immune response in a parkinsonian allograft rat model: Influence on graft-derived aberrant behaviors. Neurobiol. Dis. 2008, 32:229-242.
76. Soderstrom K.E., O'Malley J.A., Levine N.D., Sortwell C.E., Collier T.J., Steece-Collier K. Impact of dendritic spine preservation in medium spiny neurons on dopamine graft efficacy and the expression of dyskinesias in parkinsonian rats. Eur. J. Neurosci. 2010, 31:478-490.
77. Soghomonian J.J. L-DOPA-induced dyskinesia in adult rats with a unilateral 6-OHDA lesion of dopamine neurons is paralleled by increased c-fos gene expression in the subthalamic nucleus. Eur. J. Neurosci. 2006, 23(9):2395-2403. Erratum in: Eur J Neurosci. 24(5):1505.
78. Steece-Collier K., Soderstrom K.E., Collier T.J., Sortwell C.E., Maries-Lad E. Effect of levodopa priming on dopamine neuron transplant efficacy and induction of abnormal involuntary movements in parkinsonian rats. J. Comp. Neurol. 2009, 515:15-30.
79. Su P.C., Ma Y., Fukuda M., Mentis M.J., Tseng H.M., Yen R.F., Liu H.M., Moeller J.R., Eidelberg D. Metabolic changes following subthalamotomy for advanced Parkinson's disease. Ann. Neurol. 2001, 50:514-520.
80. Tai C.H., Boraud T., Bezard E., Bioulac B., Gross C., Benazzouz A. Electrophysiological and metabolic evidence that high-frequency stimulation of the subthalamic nucleus bridles neuronal activity in the subthalamic nucleus and the substantia nigra reticulata. FASEB J. 2003, 17:1820-1830.
81. Toda H., Hamani C., Lozano A. Deep brain stimulation in the treatment of dyskinesia and dystonia. Neurosurg. Focus 2004, 17:E2.
82. Wessell R.H., Ahmed S.M., Menniti F.S., Dunbar G.L., Chase T.N., Oh J.D. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats. Neuropharmacology 2004, 47:184-194.
83. Windels F., Bruet N., Poupard A., Urbain N., Chouvet G., Feuerstein C., Savasta M. Effects of high frequency stimulation of subthalamic nucleus on extracellular glutamate and GABA in substantia nigra and globus pallidus in the normal rat. Eur. J. Neurosci. 2000, 12:4141-4146.
84. Windels F., Bruet N., Poupard A., Feuerstein C., Bertrand A., Savasta M. Influence of the frequency parameter on extracellular glutamate and gamma-aminobutyric acid in substantia nigra and globus pallidus during electrical stimulation of subthalamic nucleus in rats. J. Neurosci. Res. 2003, 72:259-267.
85. Windels F., Carcenac C., Poupard A., Savasta M. Pallidal origin of GABA release within the substantia nigra pars reticulata during high-frequency stimulation of the subthalamic nucleus. J. Neurosci. 2005, 25:5079-5086.
86. Wullner U., Standaert D.G., Testa C.M., Landwehrmeyer G.B., Catania M.V., Penney J.B., Young A.B. Glutamate receptor expression in rat striatum: effect of deafferentation. Brain Res. 1994, 647:209-219.
87. Yelnik J., Damier P., Bejjani B.P., Francois C., Gervais D., Dormont D., Arnulf I., Bonnet A.M., Cornu P., Pidoux B., Agid Y. Functional mapping of the human globus pallidus: contrasting effect of stimulation in the internal and external pallidum in Parkinson's disease. Neuroscience 2000, 101:77-87.